224178-67-0

Basic information

• Product Name: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE
• Synonyms: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE;4-(4-Cyanophenoxy)piperidine;3-Methoxy-4-(piperidin-4-yloxy)benzonitrile hydrochloride
• CAS NO: 224178-67-0
• Molecular Formula: C₁₂H₁₄N₂O
• Molecular Weight: 202.25
• Mol File: 224178-67-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 366.8 °C at 760mmHg
• Flash Point: 175.6 °C
• Appearance: /
• Density: 1.13
• Vapor Pressure: 1.43E-05mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(224178-67-0)
• EPA Substance Registry System: 4-(PIPERIDIN-4-YLOXY)BENZONITRILE(224178-67-0)

Safety Data

• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 224178-67-0(Hazardous Substances Data)

Usage

General Description

4-(piperidin-4-yloxy)benzonitrile is a chemical compound with the molecular formula C14H16N2O. It is a pale yellow solid that is soluble in organic solvents such as methanol and ethanol. 4-(PIPERIDIN-4-YLOXY)BENZONITRILE is commonly used as a building block in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It has a piperidine group attached to a benzene ring, as well as a nitrile group, which gives it potential for a wide range of applications in chemical synthesis. The compound's structure and properties make it a valuable reagent for organic chemistry research and development.

InChI:InChI=1/C12H14N2O/c13-9-10-1-3-11(4-2-10)15-12-5-7-14-8-6-12/h1-4,12,14H,5-8H2

Upstream product

• 5382-16-1 4-HYDROXYPIPERIDINE 
• 1194-02-1 4-fluorobenzonitrile 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 118811-07-7 tert-butyl 4-(tosyloxy)piperidin-1-carboxylate 
• 767-00-0 4-cyanophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 623-03-0 4-Cyanochlorobenzene 
• 333954-86-2 4-(4-cyano phenoxy)piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 397275-27-3 4-((1-cyclobutylpiperidin-4-yl)oxy)benzonitrile 
• 1394808-23-1 N-[4-(1-cyclobutylpiperidin-4-yloxy)benzyl]morpholine-4-ylamide 
• 1394808-77-5 4-(1-cyclobutyl piperidin-4-yloxy)benzylamine 
• 1356625-87-0 N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4-cyanophenoxy)piperidin-1-yl)picolinamide 

Relevant articles and documents

Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase

Multi-target inhibitors have become increasing popular as a means to leverage the advantages of poly-pharmacology while simplifying drug delivery. Here, we describe dual inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), two targets known to synergize when treating inflammatory and neuropathic pain. The structure activity relationship (SAR) study described herein initially started with t-TUCB (trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid), a potent sEH inhibitor that was previously shown to weakly inhibit FAAH. Inhibitors with a 6-fold increase of FAAH potency while maintaining high sEH potency were developed by optimization. Interestingly, compared to most FAAH inhibitors that inhibit through time-dependent covalent modification, t-TUCB and related compounds appear to inhibit FAAH through a time-independent, competitive mechanism. These inhibitors are selective for FAAH over other serine hydrolases. In addition, FAAH inhibition by t-TUCB appears to be higher in human FAAH over other species; however, the new dual sEH/FAAH inhibitors have improved cross-species potency. These dual inhibitors may be useful for future studies in understanding the therapeutic application of dual sEH/FAAH inhibition.

Tankyrase inhibitor

The invention belongs to the technical field of medicines and particularly relates to a tankyrase inhibitor represented by a general formula (I) shown in the description and pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof, wherein R1, R2, R3, m, n, Z, L, Q, A, X1, X2 and Y are as defined in the description. The invention further relates to a preparation method for the compounds, pharmaceutical preparations and pharmaceutical compositions containing the compounds and application of the compound and the pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof in preparation of drugs for treating and/or preventing tankyrase mediated cancers and related diseases.

NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS

The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pha